



ASX Limited  
Market Announcements Office

## CEO Quarterly Update

16 February 2016, Melbourne, Australia:

Phosphagenics Limited (ASX: POH; OTCQX: PPGNY) invites interested parties to participate in a teleconference.

The details to join the teleconference are below:

Date: Friday, 19 February 2016

Time: 9:00 am AEST

**Conference ID: 585342**

### Participant Dial-in Numbers

All participants will be asked to provide the Conference ID when joining the call.

<b>Australia Toll Free</b>	<b>1800 908 299</b>		
<b>Australia Local:</b>	<b>+61 2 9007 8048</b>		
Australia Alt. Toll Free:	1800 455 963	Indonesia Toll Free:	007 803 321 8057
Australia Alt. Local:	+61 7 3145 4005	Ireland Toll Free:	1800 948 607
New Zealand Toll Free:	0800 452 795	Japan Toll Free:	0066 3386 8000
Auckland Local:	+64 9 929 3905	Malaysia Toll Free:	1800 816 441
Canada/USA Toll Free:	1855 624 0077	Singapore Toll Free:	800 101 2702
China Toll Free:	1080 0140 1776	South Africa Toll Free:	0800 984 013
France Toll Free:	0800 913 734	Switzerland Toll Free:	0800 802 498
Germany Toll Free:	0800 183 0918	Taiwan Toll Free:	0080 112 7377
Hong Kong Toll Free:	800 968 273	UAE Toll Free:	8000 3570 2706
India Toll Free:	000 800 100 8070	UK Toll Free:	0800 051 1453

### Q&A Instructions

In order to ask a question during the Live Question and Answer Session:

Press \* then 1 on your telephone keypad to enter the Q&A queue

Press \* then 2 on your telephone keypad to withdraw your question.

## **Enquiries**

Dr Ross Murdoch  
Phosphagenics Limited  
+61 3 9565 1119

Kyahn Williamson  
Buchan Consulting  
+61 3 9866 4722 / +61 40 101 8828  
Email: [kwilliamson@buchanwe.com.au](mailto:kwilliamson@buchanwe.com.au)

## **About Phosphagenics**

Phosphagenics Limited is focused on developing and commercialising innovative Human Health, Animal Health and Personal Care products using its proprietary drug delivery system called TPM<sup>®</sup> (Targeted Penetration Matrix). TPM<sup>®</sup> is derived from Vitamin E using a unique, proprietary and patented process and has been proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Amongst its major projects, Phosphagenics' is developing a TPM<sup>®</sup> enhanced oxycodone patch for the treatment of pain associated with Postherpetic neuralgia (presently completing Phase 2a) and is also developing TPM<sup>®</sup> to enhance the feed efficiency and health of livestock.

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

[www.phosphagenics.com](http://www.phosphagenics.com)